Bugs May Be Regaining the Upper Hand Over Once Effective Antibiotics

Antibiotic resistance and rare diseases were among the topics explored by a panel of scientists and pharmaceutical industry representatives in Marburg, Germany.

By Dr. Lutz Bonacker

May 8, 2017

Philipps University of Marburg, Germany, where members of the scientific and pharmaceutical communities examined a range of timely topics.

Earlier this year I joined distinguished members of the scientific and pharmaceutical communities for an academic panel hosted by Philipps University of Marburg, Germany, where CSL Behring operates a manufacturing and R&D facility for recombinant and plasma-derived coagulation factors, C-1 inhibitor and critical care products.

Continue reading

Smart Partnerships Benefit Patients

April 2, 2015

By Jeannie Joughin, Ph.D.

Patient with New Injection-System

The patient experience can be significantly enhanced by more convenient delivery systems.

Forming partnerships with other organizations when it makes sense to do so is an important part of CSL Behring’s business strategy. One organization alone cannot address the world’s most pressing issues, such as treating rare or serious diseases. Together, partnerships can accomplish far more than individual standalones. Collaborations can unite strengths and unleash unprecedented capabilities.
Continue reading

Posts represent the opinion of the author and do not necessarily reflect the views of CSL Behring.
This site is not intended as a forum for discussing CSL Behring or other companies' products.
Comments on this blog may be reviewed by CSL Behring and may be subject to removal if they are deemed to have inappropriate content.